In fact, the drug’s prescribing information even warns about this potential side effect, Nassar noted. “Our research highlights the safety and the potential for GLP-1 receptor agonists [like semaglutide] to reduce the risk of acute pancreatitis recurrence in individuals with obesity and typ...
A1C=glycated hemoglobin; SGLT-2i=sodium-glucose cotransporter-2 inhibitor. What are you waiting for? Learn about our tool that allows you to find a patient’s coverage status and get an estimated prescription cost in minutes. Check patient costs ...
[3]Namour F, et al. AB0460?Glpg0634, A Selective JAK1 Inhibitor, Confirms Its Low Liability for Drug-Drug Interactions. Ann Rheum Dis73:960 (2014). [4] Namour F, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor,...
This “A1” state is typified by inflammatory transcriptional responses, a downregulation of phagocytic function, and neurotoxic activity that likely involve activation of toll-like receptor (TLR) 4 on the cell membrane and the downstream triggering of the inhibitor of κB kinase (IKK)-NF-κB and...
Moreover, D-hpCAFs were also treated with a selective P4HA1 inhibitor, 1,4-DPCA (Suppl. Figure 4G and 4H) [70]. Thereafter, collagen hydrogel contraction assay was performed and the strong contraction capacity of D-hpCAFs was prevented (Suppl. Figure 4B, 4E and 4G). To further confirm...
GLPG1690 is a novel autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis (IPF).
A population-based study of SGLT2 inhibitor-associated postoperative diabetic ketoacidosis in patients with type 2 diabetes. Drug Saf. 2023;46(1):53–64. doi:10.1007/s40264-022-01247-3. (Open in a new window)PubMed (Open in a new window)Web of Science ®(Open in a new window)...
Since such actions of GLP-1 are useful for improving diabetes and other lifestyle-related diseases, a GLP-1 analogue (GLP-1 receptor agonist) or an inhibitor of dipeptidyl peptidase IV (DPP-IV) which is a blood GLP-1-degrading enzyme is used in treatment of diabetes or the like. A GLP...
To investigate whether the ability of GLP-1-transfected cells to release insulin in a glucose-dependent fashion was dependent upon cAMP-dependent GLP-1 signaling, we tested the effect of the cAMP inhibitor RP-cAMP (which blocks the activation of protein kinase A, PKA, resulting from an elevatio...
AB0460Glpg0634, A Selective JAK1 Inhibitor, Confirms Its Low Liability for Drug-Drug Interactionsdorstenia speciesantitrichomonalantioxidant activityprenylated flavonoidsBackgroundGLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Less selective JAK inhibitors have shown long-...